一种Pioglitazone纳米配方设计用于癌症相关的纤维细胞重编程和癌症治疗
Shevanuja Theivendran1, He Xian1, Jingjing Qu1
1Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Brisbane 4072, Australia.
Nano letters
|April 2, 2024
概括
这项研究开发了带有pioglitazone的新型纳米粒子,用于重编程乳腺瘤中的癌症相关纤维细胞 (CAFs). 这种方法可以提高化疗药物透率,抑制瘤生长,提高治疗效率.
科学领域:
- 在瘤学瘤学.
- 纳米医学是一种纳米医学.
- 生物材料是一种生物材料.
背景情况:
- 瘤微环境 (TME) 通常会抑制抗癌免疫反应,阻碍治疗的有效性.
- 在TME内,与癌症相关的纤维细胞 (CAF) 形成屏障,促进瘤的进展和耐药性.
- 将CAF重编程到一个不那么免疫抑制的状态是改善癌症治疗结果的关键策略.
研究的目的:
- 设计和评估一种新的纳米配方,用于在乳腺癌中重新编程CAF.
- 为了研究通过纳米颗粒传递的pioglitazone的有效性,用于CAF调制.
- 评估这种方法对治疗药物透和瘤生长抑制的影响.
主要方法:
- 开发了与皮奥格利塔 (DMON-P) 装载的对谷氨 (GSH) 敏感的树突性半孔性有机纳米颗粒.
- DMON-P的设计是为了有针对性地向乳腺癌TME中的CAFs的富含GSH的细胞质提供.
- 在临床前模型中评估DMON-P对CAF重编程,增强多克索鲁比辛 (Dox) 透和抑制瘤生长的能力.
主要成果:
- DMON-P成功地向CAF输送了皮奥格利塔,调解了它们的重编程.
- 纳米配方增强了多克索鲁比辛 (Dox) 透到瘤中的作用.
- 用DMON-P治疗导致CAF生物标志物的下调,并显著抑制瘤生长.
结论:
- 装有pioglitazone的纳米颗粒提供了一个有希望的策略来重新编程CAFs在乳腺癌TME.
- 这种方法可以克服CAFs带来的治疗障碍,提高药物输送和疗效.
- DMON-P代表了一种新的治疗途径,用于改善CAF丰富的瘤,特别是乳腺癌的结果.
更多相关视频
08:35Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
28.2K
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
13.0K
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
01:24Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
01:23Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K